The global antifungal drug market, by drug type (echinocandins,polyenes, allylamines, azoles, and others), indication (aspergillosis,dermatophytosis, candidiasis, mucormycosis, and others), dosage form (powders,ointments, drugs, and others), and region (North America, Latin America,Europe, Asia Pacific, Middle East, and Africa), is expected to be worth(2021-2028).
Over theprojected period, the global antifungal drug market medicines market isexpected to be constrained by the COVID-19 pandemic. COVID-19 has posed athreat to a variety of sectors and markets around the world. The proliferationof COVID-19 has had a negative impact on pharmaceutical businesses, healthcareinstitutions, pharmaceutical distribution, and retail sectors in the shortterm. As of May 18th, 2021, the manifestation of coronavirus illness (COVID-19)had resulted in more than 4.8 million new cases and approximately 86 000 newdeaths worldwide, according to the World Health Organization.
The global antifungaldrug market medications was valued at USD 11.3 billion in 2017. One of themajor drivers of the market is the rising occurrence of fungal illnesses suchas aspergillosis and candidiasis. Fungal infections include skin, eye, mouth,and vaginal infections, as well as systemic and superficial infections.Antifungal medications having fungicidal action are commonly used to treat avariety of fungal-related disorders, including athlete's foot, ringworm, andfungal meningitis. Furthermore, rising incidences of patients withhospital-acquired or nosocomial infections and infectious disorders areexpected to fuel market expansion during the forecast period.
Furthermore,increasing public-private partnerships in the pharmaceutical industry for thediscovery of innovative treatments are expected to provide the market withsignificant potential prospects. For example, CARB-X, an internationalpublic-private collaboration, is expected to contribute roughly USD 350 millionto the R&D pipeline over the next five years. The US Department of Healthand Human Services, the Antimicrobial Resistance Centre in England, and BostonUniversity School of Law are among the collaborators.
Leadingtherapeutic agents such as Noxafil, Vfend, Diflucan, and Cresemba dominated theAzoles medication class in 2017. Azoles' broad-spectrum action is responsiblefor the company's market supremacy. By inhibiting fungal enzymes, these drugsaid in fungistatic activity. Candemia, blastomycosis, systemic candidiasis, andocular fungal infections are all treated with azoles.
Antifungalmedication research is picking up steam, thanks to the development of newazole-based Antifungal drug market. Azoles are synthetic andsemi-synthetic chemicals that are commonly used to treat fungal infections,both superficial and invasive. Thrush, yeast infection, candidiasis,aspergillosis, tinea versicolor, athlete's foot, jock itch, ringworm, nailfungus, fungal infections, systemic mycosis, and seborrheic dermatitis are alltreated with these medications. Triazoles (fluconazole, itraconazole,voriconazole, posaconazole, and isavuconazole) and imidazoles (fluconazole,itraconazole, voriconazole, posaconazole, and isavuconazole) are two types ofantifungal azoles (ketoconazole).
In theUnited States, fungal illnesses have been a problem to the country's healthcareauthorities. People all throughout the world, including those in the UnitedStates, have developed resistance to the treatments that are currentlyaccessible. Resistance against some forms of Candida (the most common cause ofhealthcare-associated bloodstream infections in the United States) has beenobserved, according to the Centers for Disease Control and Prevention (CDC).
Antifungaldrug market medicationsare expected to reach a global market size of USD 13.8 billion by 2025, with a1.9 percent annual growth rate. Serious fungal infections were previouslyuncommon, owing to the low climate. Fungal infections cause minor discomfortand were rarely life-threatening in those days. However, over the last fewyears, the incidence rate of fungal illnesses has steadily increased. Theincreased number of patients susceptible to fungal infections was one factoraiding the spread of these diseases.
Invasivepulmonary aspergillosis, cryptococcal meningitis or endocarditis, andrhinocerebral mucormycosis are some of the more dangerous fungal infections.Invasive pulmonary aspergillosis is one of them, with invasive pulmonaryaspergillosis being the primary cause of death in several nations (developed aswell as developing).
